OUTCOMES OF BLINATUMOMAB THE INITIAL PHASE OF CHEMOTHERAPY IN CHILDREN WITH B-CELL ALL

Аннотация

This retrospective single‑center study (2020–2024) from the Pediatric Oncology Center in Tashkent evaluated the efficacy of incorporating blinatumomab (14‑day courses at 15 μg/m²/day, twice with a two‑month interval) into the ALL‑MB‑2015 protocol for children with B‑cell ALL who remained MRD‑positive post‑induction. All 25 patients achieved hematologic remission; MRD dropped from 12 % to 0.001 % after the first blinatumomab course, and remained negative after the second. Median follow‑up was 2.5 years. There were two late relapses (in standard‑ and intermediate‑risk groups), 4‑year EFS was 88.1 ± 3.7 %, and no deaths occurred. Adverse events (allergic reactions, neurotoxicity, hypoalbuminemia, cytopenias) were manageable.